Drug Profile
Arbaclofen - AGI Therapeutics
Alternative Names: AGI-006; R-baclofen - AGI TherapeuticsLatest Information Update: 15 May 2014
Price :
$50
*
At a glance
- Originator AGI Therapeutics
- Class Aminobutyric acids; Behavioural disorder therapies; Gastrokinetics; Muscle relaxants; Small molecules
- Mechanism of Action GABA B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Gastro-oesophageal reflux; Gastroparesis; Nausea and vomiting
- Discontinued Non-ulcer dyspepsia
Most Recent Events
- 15 May 2014 No development reported - Preclinical for Gastro-oesophageal reflux in Europe (PO)
- 15 May 2014 No development reported - Preclinical for Gastroparesis in Europe (PO)
- 15 May 2014 No development reported - Preclinical for Nausea and vomiting in Europe (PO)